Phase II trial shows activity of durvalumab in recurrent/metastatic head and neck cancer

(American Society for Radiation Oncology) Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow growth in tumors with low or negative expression of the PD-L1 protein.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news